Peringkat dalam Saham
#31262
Noxopharm Limited is an Australian drug development company with an... Noxopharm Limited is an Australian drug development company with an international reach, focused on pioneering new treatment options for a range of solid tumor cancers and septic shock. Its primary asset, Veyonda, functions as an adjuvant therapy designed to augment the effectiveness of chemotherapy and radiotherapy in treating late-stage cancers. Beyond Veyonda, the company's robust development pipeline encompasses several key programs: The DARRT program, currently in Phase 1b/2a clinical trials, is addressing metastatic castration-resistant prostate cancer and other solid tumors. The LuPIN program explores a combined therapy of Veyonda and 177Lu-PSMA-617 for advanced prostate cancer. The IONIC program combines Veyonda with Bristol Myers Squibb's checkpoint inhibitor, Opdivo, targeting various solid tumor types. Its Chemotherapy Enhancement Program (CEP) integrates Veyonda with carboplatin for patients suffering from refractory solid tumors in areas such as the breast, head and neck, lung, prostate, and ovaries. Furthermore, the NOXCOVID Program is conducting a dose escalation and expansion study of NOX66 for the treatment of COVID-19 infection. The company is also investigating potential treatments for pancreatic cancer and glioblastoma. Noxopharm collaborates with the Hudson Institute of Medical Research and The Australian National University on the research and development of therapeutic drugs for inflammatory disorders. Incorporated in 2015, the company's operations are based in Chatswood, Australia.
Kapitalisasi Pasar
$13.65M
Perubahan (1 tahun)
-32.53%
Perdagangan Noxopharm Limited (NOX)
Pendapatan untuk Noxopharm Limited (NOX)
Pendapatan pada Jun 2026 TTM: 0.00
Menurut laporan keuangan terbaru dari Noxopharm Limited, pendapatan saat ini (TTM) adalah 0.00. Pada tahun 2024, perusahaan menghasilkan pendapatan sebesar $1.60M penurunan dibandingkan dengan pendapatan pada tahun 2023 yang sebesar $4.00M. Pendapatan adalah jumlah total yang dihasilkan dari penjualan barang atau jasa. Tidak seperti laba, tidak ada pengeluaran yang dikurangkan.
Riwayat pendapatan Noxopharm Limited dari 2016 hingga 2026
Pendapatan pada akhir setiap tahun
| Tahun |
Pendapatan |
Mengubah |
|
2026 (TTM) |
0.00 |
-100.00%
|
|
2025 |
$1.86M |
15.87%
|
|
2024 |
$1.60M |
-59.98%
|
|
2023 |
$4.00M |
6.95%
|
|
2022 |
$3.74M |
-10.96%
|
|
2021 |
$4.21M |
-26.42%
|
|
2020 |
$5.71M |
116.95%
|
|
2019 |
$2.63M |
288.04%
|
|
2018 |
$678.81K |
597.95%
|
|
2017 |
$97.26K |
0.00%
|
|
2016 |
0.00 |
0.00%
|
Pendapatan untuk perusahaan serupa atau pesaing
| Perusahaan |
Pendapatan |
Perbedaan Pendapatan |
Negara |
|
|
$12.62B |
-
|
US
|
|
|
$2.23B |
-
|
US
|
|
|
$15.74B |
-
|
AU
|
|
|
$6.02B |
-
|
NL
|
|
|
- |
-
|
CH
|
